A Patient with CA19-9-Producing Pulmonary Adenocarcinoma Who Responded to Multidisciplinary Therapy and Achieved Complete Response

• Published in: Gan to kagaku ryoho Vol. 43; no. 7; p. 885
• Main Authors: Katayama, Kazuhisa, Tanaka, Takashi, Takahashi, Yuji, Endo, Hideko
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.07.2016
• Subjects: Adenocarcinoma - chemistry; Adenocarcinoma - drug therapy; Adenocarcinoma - metabolism; Adenocarcinoma - surgery; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; CA-19-9 Antigen - analysis; CA-19-9 Antigen - biosynthesis; Carboplatin - administration & dosage; Chemotherapy, Adjuvant; Humans; Lung Neoplasms - chemistry; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - surgery; Lymph Node Excision; Male; Neutropenia; Paclitaxel - administration & dosage
• ISSN: 0385-0684

The patient, a man in his 60s, visited his physician with hemosputum. The shadow of a large mass, measuring approximately 6 cm in diameter, was observed in the left upper lung field, and the patient was referred to our hospital. After thorough examination, the mass was diagnosed as a pulmonary adenocarcinoma. In addition, serum CA19-9 levels were elevated(608.9 U/mL). Based on the PET-CT scan, the cancer was diagnosed as cT2bN1M0, stage II B disease and surgery was performed. The thorax was opened via a posterolateral incision; left upper lobectomy and lymph node dissection(ND2a-2)were performed. The lesion, measuring 56×59×44 mm, was excised from S1+2. The histopathological diagnosis was poorly-differentiated adenocarcinoma(mucin-producing adenocarcinoma). On immunostaining, the lesion was CA19-9-positive and was confirmed as pT2bN1M0, stage II B disease. The serum CA19-9 level was still elevated after surgery(83.2 U/mL). Therefore, 6 courses of adjuvant chemotherapy(carboplatin plus weekly paclitaxel)were administered. Grade 2 adverse events included hair loss and neutropenia. Thus, the drug withdrawal period was extended. After completion of 2 courses of the therapy, the serum CA19-9 level normalized. Two years after surgery, there has been no sign of recurrence.